Curis, Inc.  

(Public, NASDAQ:CRIS)   Watch this stock  
Find more results for CRIS
-0.02 (-0.72%)
After Hours: 2.74 0.00 (0.00%)
Nov 30, 5:36PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.71 - 2.82
52 week 1.09 - 3.75
Open 2.79
Vol / Avg. 335,373.00/327,416.00
Mkt cap 353.72M
P/E     -
Div/yield     -
EPS -0.47
Shares 128.39M
Beta 1.64
Inst. own 57%
Feb 22, 2016
Q4 2015 Curis Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 9, 2015
Q3 2015 Curis Inc Earnings Release
Nov 9, 2015
Q3 2015 Curis Inc Earnings Call
Oct 21, 2015
Curis Inc at Biotechnology Industry Organization (BIO) Investor Forum
Sep 10, 2015
Curis Inc at Robert W Baird and Co Health Care Conference
Sep 9, 2015
Curis Inc at FBR Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -271.06% -190.27%
Operating margin -236.86% -161.14%
EBITD margin - -159.57%
Return on average assets -20.43% -26.16%
Return on average equity -28.40% -49.97%
Employees 35 -
CDP Score - -


4 Maguire Rd
LEXINGTON, MA 02421-3112
United States - Map
+1-617-5036500 (Phone)
+1-617-5036501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Curis, Inc. (Curis) is a biotechnology company. The Company is engaged in the development and commercialization drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis' product pipeline also includes CUDC-427, an orally available, small molecule antagonist of inhibitor of apoptosis (IAP) proteins. CUDC-907 is in Phase I clinical trial stage for the treatment of advanced lymphomas and multiple myeloma, and human epidermal growth factor receptor 2 (HER 2-), estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+) breast cancer and NUT midline carcinoma. CUDC-427 is in Phase I clinical trial stage for the treatment of advanced solid tumor and lymphomas. The Company's PD-L1 antagonist and IRAK4 Inhibitor drug candidates are in preclinical stage of development.

Officers and directors

James R. McNab Jr. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Ali Fattaey Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Daniel R. Passeri J.D. Vice Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Michael P. Gray Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jaye Viner M.D. Chief Medical Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Kenneth J. Pienta M.D. Director
Age: 55
Bio & Compensation  - Reuters
Martyn D. Greenacre Independent Director
Age: 73
Bio & Compensation  - Reuters
Kenneth I. Kaitin Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Robert E. Martell M.D., Ph.D. Independent Director
Age: 52
Bio & Compensation  - Reuters
Marc Rubin M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters